JIUN-KAE JACK LEE to Proto-Oncogene Proteins c-akt
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Proto-Oncogene Proteins c-akt.
Connection Strength
0.194
-
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82.
Score: 0.059
-
Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6.
Score: 0.038
-
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
Score: 0.018
-
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87.
Score: 0.017
-
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
Score: 0.017
-
PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
Score: 0.016
-
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84.
Score: 0.015
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.015